Evidence map›Paper›PMID 37121717›Full record

ArticleJournal of clinical and experimental hematopathology : JCEH2023

Role of TGF-beta1 and TNF-alpha1 produced by neoplastic cells in the pathogenesis of fibrosis in patients with hematologic neoplasms.

Haruko Takizawa, Yoshihiko Araki, Maki Fujishiro, Shigeki Tomita, Satsuki Kishikawa, Akane Hashizume, Toru Mitsumori, Hideaki Nitta, Hiroko Iizuka-Honma, Tomohiro Sawada and 4 more

Open access · goldAbstract read
In one paragraph

Article in Journal of clinical and experimental hematopathology : JCEH, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
2.1field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. About a Possible Impact of Endodontic Infections byInternational journal of molecular sciences · 2024
    Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 4 institutions in 1 country.

Haruko TakizawaDepartment of Hematology, Juntendo University Urayasu Hospital, Chiba, Japan.
Yoshihiko ArakiDepartment of Pathology and Microbiology, Division of Microbiology, Nippon University School of Medicine, Tokyo, Japan.
Maki FujishiroInstitute for Environmental and Gender-Specific Medicine, Juntendo University Urayasu Hospital, Chiba, Japan.
Shigeki TomitaDepartment of Diagnostic Pathology, Juntendo University Urayasu Hospital, Chiba, Japan.
Satsuki KishikawaDepartment of Diagnostic Pathology, Juntendo University Urayasu Hospital, Chiba, Japan.
Akane HashizumeDepartment of Diagnostic Pathology, Juntendo University Urayasu Hospital, Chiba, Japan.
Toru MitsumoriDepartment of Hematology, Juntendo University Urayasu Hospital, Chiba, Japan.
Hideaki NittaDepartment of Hematology, Juntendo University Urayasu Hospital, Chiba, Japan.
Hiroko Iizuka-HonmaDepartment of Hematology, Juntendo University Urayasu Hospital, Chiba, Japan.
Tomohiro SawadaDepartment of Clinical Laboratory, Juntendo University Urayasu Hospital, Chiba, Japan.
Mitsuo OkuboLaboratory of Blood Transfusion, Juntendo University Urayasu Hospital, Chiba, Japan.
Yasunobu SekiguchiHematology Clinic, Saitama Cancer Center, Saitama, Japan.
Miki AndoDivision of Hematology, Juntendo University Juntendo Hospital, Tokyo, Japan.
Masaaki NoguchiDepartment of Hematology, Juntendo University Urayasu Hospital, Chiba, Japan.
Juntendo University Urayasu Hospital · JPJuntendo University Hospital · JPNippon Medical School · JPSaitama Cancer Center · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We conducted this study with the objective of elucidating the mechanism of development of fibrosis in hematologic neoplasms and develop treatments for these patients. Among the suggested mechanisms of development of fibrosis is cases of hematologic neoplasms is the production of TGF-beta1 (transforming growth factor-beta-1) and TNF-alpha1 (tumor necrotizing factor-alpha-1) by the tumor cells, both of which are fibrosis-stimulating cytokines that act on fibroblasts to promote fibrosis. However, there are few reports based on human clinical pathology studies. We conducted an immunohistochemical study on paraffin-embedded formalin-fixed specimens obtained from 104 patients with various pathologic conditions (acute leukemia, malignant lymphoma, inflammation, cancer, etc.). The association of tissue fibrosis with positive immunohistochemistry for TGF- beta1 and/or TNF-alpha1, TGF-beta1 was found to be strongly associated with tissue fibrosis, and in cases with positive immunohistochemistry for TGF-beta1, the odds ratio for fibrosis was 12.8, which was significantly high. Combined positivity for TGF-beta1 and TNF-alpha1 was also associated with a significant odds ratio for fibrosis of 3.4, suggesting that TGF-beta1 expression is an important prerequisite. TGF-beta1 has been suggested as playing a relatively important role in tissue fibrosis. Future clinical application of these cytokines for both diagnosis and treatment is expected.

Indexed as

Hematologic NeoplasmsTransforming Growth Factor beta1CytokinesFibrosisHumansTransforming Growth Factor betaCytokinesTransforming Growth Factor betaTransforming Growth Factor beta1fibrosishematologic neoplasmsTGF-beta1TNF-alpha1

Identifiers

PMID37121717
PMCPMC10410624
OpenAlexW4367276437

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.